Form 4: Neogenomics CEO Anthony P. Zook Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
CEO Anthony P. Zook reports the acquisition of stock options and restricted stock units in Neogenomics Inc.
Summary
- On April 3, 2025, Anthony P. Zook, CEO of Neogenomics Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates that Mr. Zook acquired 729,927 stock options with an exercise price of $10.44 on April 1, 2025, vesting ratably over three years and expiring on April 1, 2035.
- Additionally, he was granted 421,496 restricted stock units on April 1, 2025, vesting ratably over three years.
- Mr. Zook also holds 8,353 stock options with an exercise price of $14.82, exercisable from August 10, 2024, and expiring on August 10, 2033.
- He also holds 8,672 stock options with an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
- Mr. Zook also holds 12,254 restricted stock units exercisable from June 1, 2025.
- Following these transactions, Mr. Zook directly owns 11,336 shares of Neogenomics common stock.
- The filing was signed by Ali Olivo, Attorney-in-Fact, on April 3, 2025.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The vesting schedules indicate a long-term focus, which is generally viewed positively.
Positives
- The grant of stock options and restricted stock units to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The vesting schedules for the stock options and restricted stock units suggest a focus on long-term performance and retention of the CEO.
Industry Context
Equity grants are a common practice in the biotech and diagnostics industry to incentivize and retain key executives. The specific terms of the grants (vesting schedule, exercise price) are tailored to the company's performance and the executive's role.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules of three years are typical for these types of grants, aligning with industry norms for long-term incentive plans.
- The premium-priced stock option with an exercise price of $10.44, calculated as 110% of the closing price on April 1, 2025, is designed to incentivize significant stock price appreciation.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see the grants as an indication of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 08/10/2024 | Date from which 8,353 stock options with an exercise price of $14.82 are exercisable. |
| 04/01/2025 | Date of the grant of 729,927 stock options and 421,496 restricted stock units. |
| 06/01/2025 | Date from which 8,672 stock options with an exercise price of $13.71 and 12,254 restricted stock units are exercisable. |
| 04/03/2025 | Date of filing the Form 4. |
| 06/01/2034 | Expiration date of 8,672 stock options with an exercise price of $13.71. |
| 08/10/2033 | Expiration date of 8,353 stock options with an exercise price of $14.82. |
| 04/01/2035 | Expiration date of 729,927 stock options with an exercise price of $10.44. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Neogenomics, CEO, Zook, Equity, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.